Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Mustang Bio

Nasdaq:MBIO
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MBIO
Nasdaq
$111M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Mustang Bio has significant price volatility in the past 3 months.
MBIO Share Price and Events
7 Day Returns
10.6%
NasdaqGM:MBIO
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-23.5%
NasdaqGM:MBIO
0%
US Biotechs
-11.5%
US Market
MBIO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mustang Bio (MBIO) 10.6% -11.2% -31.7% -23.5% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • MBIO underperformed the Biotechs industry which returned 0% over the past year.
  • MBIO underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
MBIO
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Mustang Bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mustang Bio. This is due to cash flow or dividend data being unavailable. The share price is $2.61.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mustang Bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mustang Bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:MBIO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.29
NasdaqGM:MBIO Share Price ** NasdaqGM (2020-03-27) in USD $2.61
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mustang Bio.

NasdaqGM:MBIO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MBIO Share Price ÷ EPS (both in USD)

= 2.61 ÷ -1.29

-2.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mustang Bio is loss making, we can't compare its value to the US Biotechs industry average.
  • Mustang Bio is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Mustang Bio's expected growth come at a high price?
Raw Data
NasdaqGM:MBIO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
7.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mustang Bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mustang Bio's assets?
Raw Data
NasdaqGM:MBIO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.29
NasdaqGM:MBIO Share Price * NasdaqGM (2020-03-27) in USD $2.61
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:MBIO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MBIO Share Price ÷ Book Value per Share (both in USD)

= 2.61 ÷ 1.29

2.02x

* Primary Listing of Mustang Bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mustang Bio is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Mustang Bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mustang Bio has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Mustang Bio expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mustang Bio expected to grow at an attractive rate?
  • Unable to compare Mustang Bio's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Mustang Bio's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Mustang Bio's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:MBIO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:MBIO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 7.3%
NasdaqGM:MBIO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 74.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:MBIO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:MBIO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 44 -19 2
2023-12-31 15 -43 2
2022-12-31 2 -70 3
2021-12-31 0 -63 3
2020-12-31 0 -56 3
2020-03-28
NasdaqGM:MBIO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -34 -46
2019-09-30 0 -31 -42
2019-06-30 0 -26 -39
2019-03-31 -20 -34
2018-12-31 -19 -31
2018-09-30 0 -18 -34
2018-06-30 0 -19 -34
2018-03-31 -16 -34
2017-12-31 -13 -31
2017-09-30 -10 -24
2017-06-30 -6 -19
2017-03-31 -6 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mustang Bio is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Mustang Bio's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:MBIO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Mustang Bio Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MBIO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.28 0.00 -0.56 2.00
2023-12-31 -0.68 -0.64 -0.72 2.00
2022-12-31 -1.18 -0.77 -1.85 3.00
2021-12-31 -1.23 -0.96 -1.68 3.00
2020-12-31 -1.19 -0.92 -1.55 3.00
2020-03-28
NasdaqGM:MBIO Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.29
2019-09-30 -1.28
2019-06-30 -1.33
2019-03-31 -1.24
2018-12-31 -1.14
2018-09-30 -1.29
2018-06-30 -1.28
2018-03-31 -1.31
2017-12-31 -1.24
2017-09-30 -1.10
2017-06-30 -1.07
2017-03-31 -1.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mustang Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Mustang Bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mustang Bio has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Mustang Bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mustang Bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mustang Bio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mustang Bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mustang Bio's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mustang Bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mustang Bio Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MBIO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -46.39 10.47 35.42
2019-09-30 -0.05 -41.95 9.15 32.67
2019-06-30 -0.05 -39.30 8.50 30.97
2019-03-31 -33.99 7.04 27.51
2018-12-31 -30.66 7.26 23.96
2018-09-30 0.05 -34.49 6.05 26.85
2018-06-30 0.05 -33.92 9.31 23.03
2018-03-31 -34.35 9.24 23.46
2017-12-31 -31.29 9.21 20.38
2017-09-30 -24.44 9.30 14.59
2017-06-30 -19.37 5.80 12.67
2017-03-31 -14.97 4.59 9.26
2016-12-31 -12.65 2.82 8.55
2016-09-30 -5.71 1.94 3.29
2016-06-30 -4.56 0.93 3.29
2016-03-31 -4.00 0.56 3.16
2015-12-31 -5.36 0.30 4.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mustang Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mustang Bio has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mustang Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mustang Bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mustang Bio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Mustang Bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mustang Bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mustang Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mustang Bio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mustang Bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mustang Bio Company Filings, last reported 2 months ago.

NasdaqGM:MBIO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 51.65 13.43 61.41
2019-09-30 62.45 13.19 72.79
2019-06-30 71.44 12.95 82.63
2019-03-31 28.48 12.73 40.64
2018-12-31 36.40 0.00 34.07
2018-09-30 44.99 0.00 40.83
2018-06-30 51.61 0.00 46.74
2018-03-31 55.64 0.00 54.76
2017-12-31 59.83 0.00 60.98
2017-09-30 65.09 0.00 67.30
2017-06-30 69.07 0.15 73.83
2017-03-31 74.21 0.03 75.01
2016-12-31 24.28 0.32 27.50
2016-09-30 3.32 4.93 11.12
2016-06-30 -6.17 4.87
2016-03-31 -5.03 4.15
2015-12-31 -4.13 3.57
  • Mustang Bio's level of debt (26%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Mustang Bio's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mustang Bio has sufficient cash runway for 1.6 years based on current free cash flow.
  • Mustang Bio has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 56% each year.
X
Financial health checks
We assess Mustang Bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mustang Bio has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Mustang Bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mustang Bio dividends.
If you bought $2,000 of Mustang Bio shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mustang Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mustang Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:MBIO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:MBIO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mustang Bio has not reported any payouts.
  • Unable to verify if Mustang Bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mustang Bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mustang Bio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Mustang Bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mustang Bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mustang Bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Mustang Bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Manny Litchman
COMPENSATION $605,512
AGE 65
TENURE AS CEO 2.9 years
CEO Bio

Dr. Manuel Litchman, also known as Manny, M.D. has been the President, Chief Executive Officer and Director at Mustang Bio Inc. since April 24, 2017. Dr. Litchman served as the Chief Executive Officer and President of Arvinas, Inc. since January 12, 2015 until February 2017. Prior to Arvinas, Dr. Litchman spent more than 18 years with Novartis Pharmaceuticals Corporation, serving in multiple positions of increasing responsibility, focusing on oncology. Most recently, Dr. Litchman served as Senior Vice President and Executive Global Program Head, CTL019, Cell & Gene Therapies Unit, where he led a collaboration with the University of Pennsylvania investigating chimeric antigen receptor modified T cells (CAR Ts) directed against CD19 on B cell malignancies. Since August 2012, he has led the CTL019 program, a Phase 2 collaboration with the University of Pennsylvania that is investigating chimeric antigen receptor modified T cells (CARTs) directed against CD19 on B cell malignancies. Prior to the start of the CTL019 collaboration he served as Head of Oncology Business Development and Licensing and Vice President at Novartis. He served as Senior Vice President and Global Program Head at Novartis Pharmaceuticals. Dr. Litchman began his career in Clinical Research at Hoffmann-La Roche, then transitioned to Sandoz/Novartis, where he led global clinical development programs. He later moved to Ursus Capital, a biotechnology hedge fund, where he held the position of Senior Equity Analyst, before eventually returning to Novartis and directed oncology / immunology clinical research at Hoffmann-La Roche Inc. He served as a Director of Arvinas, Inc. Dr. Litchman earned BA from Princeton University and M.D. degree at Yale University School of Medicine and completed his internal medicine residency and his hematology-oncology fellowship at New York Presbyterian Hospital/Weill Cornell Medical Center.

CEO Compensation
  • Manny's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Manny's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Mustang Bio management team in years:

2.2
Average Tenure
55.5
Average Age
  • The tenure for the Mustang Bio management team is about average.
Management Team

Mike Weiss

TITLE
Executive Chairman
COMPENSATION
$139K
AGE
53
TENURE
3.2 yrs

Manny Litchman

TITLE
President
COMPENSATION
$606K
AGE
65
TENURE
2.9 yrs

Brian Achenbach

TITLE
Senior VP of Finance & Corporate Controller
COMPENSATION
$301K
AGE
54
TENURE
2.4 yrs

Knut Niss

TITLE
Chief Technology Officer
TENURE
2 yrs

Debra Manning

TITLE
Vice President of Human Resources
TENURE
1.2 yrs

Martina Sersch

TITLE
Chief Medical Officer
TENURE
1.4 yrs

Robyn Hunter

TITLE
Corporate Secretary
AGE
57
Board of Directors Tenure

Average tenure and age of the Mustang Bio board of directors in years:

3.8
Average Tenure
60.5
Average Age
  • The tenure for the Mustang Bio board of directors is about average.
Board of Directors

Mike Weiss

TITLE
Executive Chairman
COMPENSATION
$139K
AGE
53
TENURE
4.8 yrs

Manny Litchman

TITLE
President
COMPENSATION
$606K
AGE
65
TENURE
2.9 yrs

Neil Herskowitz

TITLE
Independent & Non-Executive Director
COMPENSATION
$129K
AGE
62
TENURE
4.6 yrs

Adam Chill

TITLE
Independent Director
COMPENSATION
$139K
AGE
51
TENURE
2.8 yrs

Lindsay Rosenwald

TITLE
Non-Executive Director
COMPENSATION
$129K
AGE
64
TENURE
5 yrs

Michael Zelefsky

TITLE
Independent Director
COMPENSATION
$129K
AGE
59
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Mustang Bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mustang Bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Are Insiders Buying Mustang Bio, Inc. (NASDAQ:MBIO) Stock?

Check out our latest analysis for Mustang Bio Mustang Bio Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Non-Executive Director Lindsay Rosenwald for US$221k worth of shares, at about US$4.41 per share. … As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. … Mustang Bio may have bought shares in the last year, but they didn't sell any.

Simply Wall St -

Such Is Life: How Mustang Bio (NASDAQ:MBIO) Shareholders Saw Their Shares Drop 66%

It seems likely some shareholders believe that Mustang Bio has the funding to invent a new product before too long. … There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders. … We'd venture that shareholders are concerned about the need for more capital, because the share price has dropped 66% in the last year.

Simply Wall St -

Should You Take Comfort From Insider Transactions At Mustang Bio, Inc. (NASDAQ:MBIO)?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'? … In the last twelve months, the biggest single purchase by an insider was when Non-Executive Director Lindsay Rosenwald bought US$221k worth of shares at a price of US$4.41 per share … That means that even when the share price was higher, an insider wanted to purchase shares

Simply Wall St -

What Kind Of Shareholder Appears On The Mustang Bio Inc's (NASDAQ:MBIO) Shareholder Register?

Generally speaking, as a company grows, institutions will increase their ownership. … We also tend to see lower insider ownership in companies that were previously publicly owned. … institutional investors have bought into the company.

Simply Wall St -

Company Info

Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase I/II clinical trials. The company also develops CD123, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; CD20 for immunotherapy of B-cell lymphomas; CS1, an NK cell receptor regulating immune functions; IL13Ra2 CAR T cell program for glioblastoma; HER2 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; and PSCA CAR T for prostate and pancreatic cancers. It has a license agreement with Harvard University for the treatment of cancer; Nationwide Children’s Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.

Details
Name: Mustang Bio, Inc.
MBIO
Exchange: NasdaqGM
Founded: 2015
$111,044,261
42,545,694
Website: http://www.mustangbio.com
Address: Mustang Bio, Inc.
2 Gansevoort Street,
9th Floor,
New York,
New York, 10014,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MBIO Common Shares Nasdaq Global Market US USD 22. Aug 2017
BST 2W6 Common Shares Boerse-Stuttgart DE EUR 22. Aug 2017
Number of employees
Current staff
Staff numbers
51
Mustang Bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:34
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/17
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.